Suite 1015
Medical College Building
Philadelphia, PA 19107
(215) 503-5253
(215) 503-9506 fax
Most Recent Peer-reviewed Publications
- Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
- Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
- Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention
- Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling
- The role of genetic counseling in familial and sporadic cancer: Considerations, challenges, and collaboration
Medical School
Jefferson Medical College - 1997
Pennsylvania State University
- 1995
Residency
University of Michigan Medical Center
Fellowship
Fox Chase Cancer Center University of Michigan Medical Center
Board Certification
Medical Oncology – Recertified 2014
American Board of Internal Medicine – Certified 2002
Hospital Appointment
Thomas Jefferson University Hospitals
University Appointment
Associate Professor
Research & Clinical Interests
Veda N. Giri, MD is an Associate Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University. She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. Dr. Giri has recently assumed the position of Director of Cancer Risk Assessment and Clinical Cancer Genetics at Thomas Jefferson University, where her role will be to lead an integrated and comprehensive effort in inherited cancer risk assessment and conduct studies focused on genetic evaluation of cancer risk. Her clinical efforts will be focused on genetic evaluation of inherited risk for GU cancers, specifically prostate, kidney, and upper tract urothelial cancers. Research studies will encompass genetic characterization of cancer risk using sequencing technologies, molecular signatures, and novel biomarkers to ultimately reduce cancer-related morbidity and mortality. Her research also has a strong focus in cancer disparities.
Dr. Giri received her medical degree from Jefferson Medical College, and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in cancer risk assessment and prostate cancer genetics.